EMA CHMP adopts positive opinion for Tabrecta in METex14 advanced NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion and recommended granting marketing authorization for Tabrecta (capmatinib) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer harboring alterations leading to mesenchymal-epithelial-transition factor gene exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


Topline overall survival results from the TROPION-Lung01 phase III trial, which previously met the dual primary endpoint of progression-free survival, numerically favored datopotamab deruxtecan compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer treated with at least one prior line of therapy. 
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.